Company intelligence / Profile preview

Wilson Therapeutics

Sweden

Ownership: Private
Development stage: Other

Overview

WTX101 demonstrated significant reduction in free copper levels (72% after three months in Phase 2); 79% of patients achieved copper control or ≥25% reduction after 24 weeks. Phase 3 pivotal study enrolled ~100 patients with hepatic/neurological symptoms, primary endpoint copper control at 48 weeks.[1]

Therapeutic areas: Rare Diseases
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Wilson Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wilson Therapeutics.

Explore the full profile